24 Hrs_1777294237270_124456903.png&w=64&q=75)
Source:
الوطن
Worm meds reduce lung tumor growth
A scientific study has shown that the drug Mebendazole, commonly used to treat parasitic worms, can slow the growth of treatment-resistant lung cancer tumors when combined with the drug Gefitinib. Laboratory experiments on cancer cells and mice revealed that the combined therapy reduces the cells' resistance to death by up to 38%, compared to 93% with Gefitinib alone. Additionally, the tumor doubling time increased to 25 days with the combined treatment, versus 6.2 days without any treatment. Gefitinib works by disrupting signals that promote cancer cell growth, while Mebendazole targets the cellular structures responsible for cell division, creating additional pressure on resistant cells and enhancing their vulnerability. These findings offer hope for treating resistant lung cancer, which is currently difficult to manage.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)